Axid AR cleared by FDA on May 9; Whitehall touting 30-minute onset of action.
This article was originally published in The Tan Sheet
Executive Summary
WHITEHALL-ROBINS' AXID AR 30-MINUTE ONSET OF ACTION in preventing heartburn is being emphasized by the company in press materials announcing FDA approval of the Rx-to-OTC switch product. The agency cleared the application for nizatidine 75 mg on May 9. The fourth OTC H2 antagonist to receive FDA switch clearance, Axid AR is indicated for the prevention of heartburn, acid indigestion and sour stomach.